10-K: Air Industries Group Reports Progress and Growth in Fiscal Year 2024, Despite Net Loss
Annual Report
Air Industries Group saw a revenue increase and backlog growth in 2024, but still reported a net loss, according to its latest 10-K filing.
Summary
- Air Industries Group's 2024 net sales reached $55.1 million, a 7% increase from 2023.
- The company's backlog grew by 19.9% to $117.9 million as of December 31, 2024.
- A new foreign-based defense and aerospace prime customer placed its first order with Air Industries Group.
- The company reported a net loss of $1.4 million for 2024.
- Total unfilled contract values, including the funded backlog and potential orders against LTAs, amounted to $271.3 million as of December 31, 2024.
- Approximately 69.9% of 2024 net sales were attributed to military aircraft end-use.
- The book-to-bill ratio improved to 1.29x in 2024 from 1.20x in 2023.
- The company invested $2.3 million in new property and equipment in 2024.
- As of March 31, 2025, the company employed 184 people.
- The company's auditor included an explanatory paragraph in their opinion as to the company's ability to continue as a going concern.
- The company is taking steps to refinance its debt, including selling shares of common stock.
Sentiment
Score: 5
Explanation: The document presents a mixed picture. While there's revenue growth and backlog expansion, the net loss and going concern warning temper the positive aspects. The need for refinancing and potential dilution add further uncertainty.
Positives
- Net sales increased by 7% to $55.1 million in 2024.
- Backlog increased by 19.9% to $117.9 million as of December 31, 2024.
- The book-to-bill ratio improved to 1.29x in 2024.
- The company secured its first order with a new foreign-based defense and aerospace prime customer.
- The company invested $2.3 million in new property and equipment in 2024.
- Net loss decreased from $2.1 million in 2023 to $1.4 million in 2024.
Negatives
- The company reported a net loss of $1.4 million for 2024.
- The company's auditor included an explanatory paragraph in their opinion as to the company's ability to continue as a going concern.
- The company must pay or refinance large portions of its indebtedness prior to December 30, 2025, and July 1, 2026.
- The company's disclosure controls and procedures and internal control over financial reporting were not effective as of December 31, 2024 due to a material weakness regarding appropriate segregation of duties with respect to and validation of data produced by certain modules of our financial IT systems.
Risks
- The company may need additional financing to fund investments in new or upgraded property or equipment.
- A reduction in budgeted or actual U.S. government spending for defense or changes in the mix of defense products could materially adversely impact the company's business.
- The company depends on revenues from components for a few aircraft programs and platforms and the cancellation or reduction of funding of them will harm the business.
- The company may lose sales if it fails to timely meet the specifications and requirements of its customers.
- The company may not be able to improve its gross margin and a reduction in future sales levels could have a disproportionate effect on its gross profit as a percentage of its net sales.
- The prices of raw materials the company uses are volatile.
- The company does not own the intellectual property rights to products it produces.
- The company is subject to strict governmental regulations relating to the environment, which could result in fines and remediation expense in the event of non-compliance.
- Cyber security attacks, internal system or service failures, and any unauthorized access to customer data will have an adverse effect on the company's business and reputation.
- The company has total indebtedness of approximately $26,283,000, large portions of which must be redeemed or refinanced prior to December 30, 2025 and July 1, 2026.
- The company has a history of net losses, needs to refinance its bank debt and the opinion of its auditor contains an explanatory paragraph as to its ability to continue as a going concern.
- There is only a limited public market for the company's common stock.
- The market price of the company's common stock is likely to be highly volatile, which could result in substantial losses to investors.
- The company can provide no assurance that its common stock will continue to be listed on the NYSE American.
- If the company fails to meet the expectations of securities analysts or investors, its stock price could decline significantly.
- Future financings or acquisitions may adversely affect the market price of the company's common stock.
- The company incurs significant costs as a result of operating as a public company, and its management is required to devote substantial effort to compliance requirements, including establishing and maintaining internal controls over financial reporting, and it may be exposed to potential risks if it is unable to comply with these requirements.
Future Outlook
The company is confident in its ability to boost sales in 2025, attain profitability, and improve its financial position, with total unfilled contract values amounting to $271.3 million as of December 31, 2024.
Management Comments
- Moving forward, our business strategy is geared towards competing and winning contracts that enable us to achieve sustainable and profitable business growth and delivering high quality reliable products to our customers.
- We are firmly focused on securing new contract awards, improving operations and successful execution.
Industry Context
The aerospace and defense industry is dominated by a select few large prime contractors, and Air Industries Group operates within this hierarchical network as a Tier One or Tier Two supplier.
Comparison to Industry Standards
- The company competes with Monitor Aerospace, a division of GKN Aerospace; Hydromil, a division of Triumph Aerospace Group; Heroux Devetek and Ellanef Manufacturing, a division of Magellan Corporation.
- These competitors have greater financial, physical and technical resources than Air Industries Group.
Legal Proceedings
- Contract Pharmacal Corp. commenced an action against Air Industries Group in 2018 relating to a sublease.
- The Appellate Division upheld the denial of Contract Pharmacals motion for summary judgement and upheld the denial of its motion to amend its Complaint.
- Regardless of the decision by the Appellate Division, Contract Pharmacal will be required to file an amended complaint.
Related Party Transactions
- During 2024, the company incurred interest expense of $472,000 in respect of the subordinated notes held by Michael Taglich, Robert Taglich and certain of their affiliates.
- As of December 31, 2024, Michael Taglich, Robert Taglich and certain of their affiliates held subordinated notes in the aggregate principal amount of $6,162,000 as a result of transactions entered into prior to January, 2024.
- Subsequent to December 31, 2024 the company repaid $1,291,000 of these related party notes.
Stakeholder Impact
- Shareholders face potential dilution from future equity issuances.
- Employees may be affected by the company's ability to secure new contracts and improve operations.
- Customers rely on the company's ability to deliver high-quality products on time.
- Suppliers are impacted by the company's ability to manage its supply chain effectively.
- Creditors are exposed to the risk of the company's ability to refinance its debt.
Next Steps
- The company plans to continue its strategy of investing in process improvements and capital equipment in 2025, although likely on a much smaller level.
- The company expects to engage in discussions during 2025 with its lender under the Current Credit Facility and related party note holders to explore potential extensions or refinancing of its obligations.
Key Dates
| Date | Description |
|---|---|
| 1941 | Air Industries Group began producing parts for World War II fighter aircraft. |
| 2005 | Air Industries Group became a public company. |
| 2006-10-24 | The Company consummated a Sale Leaseback Arrangement, whereby the Company sold the buildings and real property located in Bay Shore, New York (the Bay Shore Property) for a purchase price of $6,200,000. |
| 2018-10-02 | Contract Pharmacal Corp. commenced an action relating to a Sublease entered into between the Company and Contract Pharmacal. |
| 2021-07-08 | The Court denied Contract Pharmacals motion for summary judgement. |
| 2024-12-19 | Registration Statement on Form S-3 declared effective. |
| 2025-03-31 | Date as of which the number of employees was recorded as 184. |
| 2025-04-09 | Date as of which there were 3,694,095 shares of the registrant's common stock outstanding. |
| 2025-04-11 | Date as of which there were 78 stockholders of record of our common stock. |
| 2025-07-01 | Semi-annual payments in the amount of $42,000 are due commencing on July 1, 2025. |
| 2026-07-01 | Related Party Notes mature. |
| 2027-12-31 | The collective bargaining agreement with the United Service Workers, IUJAT, Local 355 expires. |
Keywords
aerospace, defense, manufacturing, precision components, assemblies, backlog, net sales, financial results, Air Industries Group
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.